With the explosive growth in number of novel immunotherapy modalities and unprecedented first-in-human trials, there are not always clear guidelines on what constitutes a succesful nonclinical filing strategy. We will review your nonclinical strategy, existing preclinical data and experimental plans to maximize the likelihood of a successful INTERACT, pre-IND meeting or IND submission. 

The first IND is only the beginning of an exciting journey toward building a comprehensive and focused portfolio of products based on your core technologies. We provide experienced advice regarding strategic considerations, competitive landscaping, resource prioritization and likelihood of scientific success to support your development of a feasible and cost-effective pipeline strategy.

The field of immunotherapy is complex and constantly evolving, with new therapies emerging every day. We offer comprehensive, rigorous scientific diligence and gap analysis so you can better understand the likelihood of real-world scientific success for your investment.